Identification and Structural Characterization of Three New Metabolites of Bupropion in Humans

Jennifer E. Sager,[†] John R. Choiniere,[†] Justine Chang,[‡] Alyssa Stephenson-Famy,[‡] Wendel L. Nelson,[§] and Nina Isoherranen^{*,†}[†]Departments of Pharmaceutics, [‡]Obstetrics and Gynecology, and [§]Medicinal Chemistry, University of Washington, Seattle, Washington 98195, United States

Supporting Information

ABSTRACT: Bupropion is a widely used antidepressant and the recommended CYP2B6 probe drug. However, current understanding of bupropion elimination pathways is limited. Bupropion has three active circulating metabolites, OH-bupropion, threohydrobupropion, and erythrohydrobupropion, but together with bupropion these metabolites and their conjugates in urine represent only 23% of the dose, and the majority of the elimination pathways of bupropion result in uncharacterized metabolites. The aim of this study was to determine the structures of the uncharacterized bupropion metabolites using human clinical samples and in vitro incubations. Three new metabolites, 4'-OH-bupropion, erythro-4'-OH-hydrobupropion, and threo-4'-OH-hydrobupropion, were detected in human liver microsome incubations and were isolated from human urine. The structures of the metabolites were confirmed via comparison of UV absorbance, NMR spectra, and mass spectral data to those of the synthesized standards. In total, these metabolites represented 24% of the drug related material excreted in urine.

KEYWORDS: Bupropion, structural characterization, metabolites, aromatic hydroxylation

Bupropion is a norepinephrine and dopamine reuptake inhibitor approved as an antidepressant¹ and for smoking cessation² and weight loss therapy.³ It is also the preferred sensitive in vivo CYP2B6 probe substrate recommended by the FDA.⁴ Yet, despite its numerous clinical and research applications, the factors contributing to the observed inter- and intraindividual variability in bupropion disposition and in its safety and efficacy are poorly understood.^{5–8}

In vivo, bupropion undergoes extensive metabolism, with <1% of the dose excreted unchanged in urine after a single oral dose.^{9–11} Much of the pharmacological activity and toxicity of bupropion is attributed to its three known primary metabolites, OH-bupropion, threohydrobupropion, and erythrohydrobupropion (Figure 1),^{12,13} which circulate at concentrations higher than bupropion.¹ OH-bupropion appears to be the main contributor to the efficacy of bupropion in smoking cessation, while both OH-bupropion and threohydrobupropion are suggested to be primarily responsible for the antidepressant activity.^{12,14,15} All three metabolites also have lower LD₅₀ values than bupropion¹¹ and cause increased convulsion risk in mice.¹⁶ Thus, it is possible that additional, yet unidentified metabolites of bupropion may also have pharmacological activity and contribute to the effects of bupropion in vivo. Such metabolites and novel metabolic pathways may also contribute to the interindividual variability in bupropion disposition, efficacy, and

Figure 1. Bupropion and its active metabolites. Red arrows indicate potential additional hydroxylation sites.

toxicity. Thus, better characterization of the elimination pathways of bupropion is necessary.

Current knowledge of bupropion metabolism is incomplete. Following a single oral radiolabeled dose, only 23% of the dose was recovered in urine as bupropion, OH-bupropion, erythrohydrobupropion, threohydrobupropion, and their conjugates (*N*- and *O*-glucuronides and sulfates^{17,18}), while 22% of the dose was excreted in urine as *m*-chlorohippuric acid and 36% as uncharacterized polar metabolites.¹¹ Possible structures

Received: May 4, 2016

Accepted: June 17, 2016

Published: June 17, 2016

Figure 2. Characterization of metabolites formed from bupropion in HLM incubations. Representative MRM chromatograms of m/z 256 $\rightarrow$ 238 (a), m/z 242 $\rightarrow$ 168 (b), and m/z 256 $\rightarrow$ 182 (c) depicting NADPH-dependent formation of OH-bupropion (a), erythro- (E) and threo- (T) hydrobupropion (b), and M1, M2, and M3 (c) and the MS/MS spectra of m/z 256 (a,c) and m/z 242 (b) for the detected metabolites. (d) Proposed fragmentation pathway of M1–M3.

of some of the uncharacterized metabolites such as aromatic hydroxylation products or products of hydroxylation of the methyl group (indicated by red arrows in Figure 1) have been proposed based on mass spectral data from *in vitro* incubations and urine samples from clinical subjects.¹⁸ Furthermore, analysis of human urine samples revealed the presence of a reduced and hydroxylated metabolite.^{18–20} However, the structures of these metabolites and their relative importance in circulation or elimination of bupropion are unknown. The goal of this study was to characterize the major unknown metabolites of bupropion, and generate standards of these metabolites for quantitative characterization of bupropion elimination pathways. These metabolites can be evaluated for their potential pharmacological and toxicological activity.

In order to identify the primary bupropion metabolites formed *in vitro*, bupropion was incubated with human liver

Figure 3. (a) Representative MRM chromatogram of m/z transition 256 $\rightarrow$ 182 from urine before and after acid deconjugation. (b) Representative MRM chromatogram of m/z transition 256 $\rightarrow$ 182 with an MS/MS spectrum of m/z 256 of M1 isolated from urine and (c) NMR spectrum of M1 isolated from urine. (d) Structure of M1 (4'-OH-bupropion) and (e) UV spectrum for M1 isolated from acid deconjugated urine.

microsomes (HLM) and metabolite formation was measured using multiple reaction monitoring (MRM) (see Supporting Information for experimental procedures). Upon incubation of bupropion with HLM, NADPH-dependent formation of six metabolites was observed (Figure 2). In addition to OH-bupropion (Figure 2a), erythrohydrobupropion and threohydrobupropion (Figure 2b), three additional monohydroxylation products (M1–M3) were detected with a parent (M + H) mass of m/z 256 and a main MRM transition of m/z 256 $\rightarrow$ 182 (Figure 2c). On the basis of ion abundance, M1 and M2 appeared to have similar importance in bupropion metabolism, while M3 formation appeared minor. All three metabolites had similar fragmentation pathways (Figures 2c,d). The main fragmentation of loss of 56 Da indicates a loss of the *t*-butyl group as isobutylene corresponding to hydroxylation outside of the *t*-butyl group. However, the fragmentation patterns did not allow for the determination of the exact hydroxylation site.

Figure 4. Characterization of metabolites formed in erythrohydrobupropion and threohydrobupropion incubations. Representative MRM chromatogram of m/z transition 258 $\rightarrow$ 184 depicting NADPH-dependent formation of M4 and M5 from erythrohydrobupropion (a) and M6 and M7 from threohydrobupropion (b) in HLM. The insets show the MS/MS spectra of m/z 258 for M4 and M5 (a) and M6 and M7 (b). (c) Representative MRM chromatogram of m/z transition 267 $\rightarrow$ 184 depicting NADPH-dependent formation of M6- d_9 and M7- d_9 following threohydrobupropion- d_9 incubation in HLM and MS/MS spectra of m/z 267 for M6- d_9 and M7- d_9 . (d) Structures of threohydrobupropion- d_9 and its potential hydroxylation products. (e) Proposed fragmentation pathways of M4–M7.

To determine whether M1–M3 are present in vivo, urine and plasma were obtained from five subjects on bupropion therapy and analyzed for M1–M3 using MRM of m/z 256 $\rightarrow$ 182. Urine was analyzed before and after acid deconjugation since sulfate and glucuronide conjugates of bupropion metabolites have been reported.¹⁸ Metabolite M1 was detectable in plasma and urine from all five subjects, while M2 was not detected in any of the samples (Supplemental Figure S2). Metabolite M3 was detected in the urine of three subjects prior to acid deconjugation, and in the acid deconjugated urine of all five subjects, but at much lower abundance than M1. Acid deconjugation markedly increased M1 and M3 ion abundance (Figure 3a), suggesting an important role for conjugation in the elimination of these metabolites.

Based on ion abundance, M1 appeared to be the predominant unknown hydroxylation product of bupropion in vitro and in vivo. To determine the structure of M1, it was extracted from acid deconjugated urine and purified using preparative chromatography. A sufficient quantity of M1 was isolated to allow structural characterization via NMR, UV–vis, and MS/MS spectroscopy (Figure 3b–e). The presence of only three protons in the aromatic region of the NMR spectrum suggested that M1 was a product of aromatic hydroxylation (Figure 3c). The hydroxylation site was assigned to the 4' position based on NMR chemical shifts and coupling constants (Figure 3c and Supporting Information). Reference standard of 4'-OH-bupropion was then synthesized and the structure of

M1 confirmed by comparison of the LC retention time (6.42 min), and MS/MS, NMR, and UV ($\lambda_{\max}$ 350 nm) spectra between the isolated metabolite and the synthesized compound (Figure 3 and Supplemental Figures S3 and S4).

Previous studies of bupropion metabolism have reported the presence of reduced and hydroxylated bupropion metabolites, yet the precursor(s) for the metabolite(s) have not been identified. To characterize the sequential metabolism, OH-bupropion, threohydrobupropion, erythrohydrobupropion, and 4'-OH-bupropion were incubated in HLM or human liver cytosol to determine which substrate(s) and subcellular fraction(s) are involved in the formation of the reduced and hydroxylated metabolite(s). NADPH-dependent formation of two hydroxylated metabolites from both erythrohydrobupropion (M4 and M5) and threohydrobupropion (M6 and M7) was detected with an $M + 1$ ion of m/z 258 and MRM transition of 258 $\rightarrow$ 184, following incubation of erythro- and threohydrobupropion in HLM (Figure 4). No NADPH-dependent formation of metabolites with m/z transitions of 258 $\rightarrow$ 184 was observed in incubations of threohydrobupropion, erythrohydrobupropion, OH-bupropion, or 4'-OH-bupropion in cytosol or following OH-bupropion incubation in HLM (Supplemental Figure S5). Based on ion abundance, metabolites M4 and M6 were the major hydroxylation products of erythro- and threohydrobupropion, respectively, while M5 and M7 appeared to be minor metabolites. Chromatograms and representative spectra for M4–M7 are shown in Figure 4. While the $[M + H]^+$ m/z 258 ion of all four metabolites (M4–

Figure 5. (a) Representative MRM chromatogram of m/z transition 258 → 184 from urine before and after acid deconjugation. (b) Representative MRM chromatogram of m/z transition 258 → 184 with the MS/MS spectra of M4 and M6 for m/z 258 and (c) NMR spectrum of M4 + M6 isolated from urine. (d) Structure of threo/erythro-4'-OH-hydrobupropion (M4 and M6) and (e) UV spectrum for M4 + M6 isolated from acid deconjugated urine.

Table 1. Percent of the Oral Bupropion Dose Recovered in Urine as Bupropion and Its Metabolites over a Steady State Dosing Interval

compound	total as free + conjugated (% of dose)	free (μmol) ^a	conjugated (μmol) ^a
bupropion	1.4 ± 1.1	59 ± 71	6.5 ± 7.3
OH-bupropion	5.0 ± 3.2	77 ± 69	110 ± 63
threohydrobupropion	21 ± 14	610 ± 550	250 ± 140
erythrohydrobupropion	1.9 ± 1	63 ± 65	22 ± 12
4'-OH-bupropion	0.8 ± 1.0	0.3 ± 0.2	29 ± 36
threo-4'-OH-hydrobupropion	5.3 ± 3.5	0.9 ± 0.9	200 ± 140
erythro-4'-OH-hydrobupropion	4.1 ± 2.7	3.3 ± 3.2	160 ± 100
<i>m</i> -chlorohippuric acid	3.0 ± 0.7	167 ± 130	
total	39 ± 15	980 ± 850	770 ± 220

^aThe molar amounts are normalized to the administered dose in each subject.

M8) suggested that these are hydroxylated metabolites of threo- and erythrohydrobupropion ($[M + H]^+$ 242), the MS/MS fragmentation patterns (Figure 4a, b) did not allow determination of hydroxylation sites. Due to the hydroxylation,

these metabolites lack the loss of 56 Da alone and lose H_2O or $\text{C}_4\text{H}_8 + \text{H}_2\text{O}$, as shown in the proposed fragmentation pathway in Figure 4e. To identify the site of hydroxylation in these compounds, threohydrobupropion-*d*₉, containing deuteriums in the *t*-butyl group, was incubated in HLM to determine whether M6 and M7 were hydroxylated in the *t*-butyl group, as was previously proposed.¹⁸ Depending on the hydroxylation site, the products were expected to differ by one Da in the $M + H$ ion, as shown in Figure 4d, allowing for detection of *t*-butyl hydroxylation. Parent masses of m/z 267 for both M6 and M7 suggested no loss of *t*-butyl deuteriums (Figure 4c), confirming that the hydroxylation was either in the aromatic ring or in the methyl group (Figure 4d).

Metabolites M4, M6, and M7 were all detectable in plasma and urine from five subjects (Figure 5 and Supplemental Figure S6). Acid deconjugation resulted in substantially greater ion abundance for M4, M6 and M7 than in untreated urine (Figure 5). Metabolite M5 was only detectable in urine following acid deconjugation (Figure 5a, Supplemental Figure S6). Based on the ion abundances from incubations and deconjugated urine, M4 and M6 were considered to be major contributors to the elimination of threo- and erythrohydrobupropion. The metabolites M4 and M6 were isolated and purified from deconjugated urine as a mixture of the erythro and threo products (Figure 5b) to allow for characterization via NMR, UV-vis, and MS/MS. The presence of three protons in the aromatic region of the NMR spectrum indicated that M4 and M6 were products of aromatic ring hydroxylation. The hydroxylation site was proposed to be at the 4'-position based on NMR chemical shifts and coupling constants. A reference standard was synthesized (Supporting Information) and the structures of M4 (erythro-4'-OH-hydrobupropion) and M6 (threo-4'-OH-hydrobupropion) were confirmed by comparison of LC retention times and NMR, UV, and MS/MS spectra between the isolated and synthesized compounds (Figure 5, Supplemental Figures S7 and S8).

To establish the relative importance of the new metabolites *in vivo*, their concentrations were quantified in plasma and urine. The dose-normalized concentrations of 4'-OH-bupropion (M1), threo-4'-OH-hydrobupropion (M4), and erythro-4'-OH-hydrobupropion (M6) in plasma were low, 12 ± 6 nM for 4'-OH-bupropion, 7 ± 1 nM for threo-4'-OH-hydrobupropion (M4), and 33 ± 20 nM for erythro-4'-OH-hydrobupropion (M6). Concentrations of all three compounds were below the lower limit of quantification (3.3 nM) in one subject. On average, 4'-OH-bupropion (M1) concentrations were less than 0.01% of those of bupropion. Circulating concentrations of threo-4'-OH-hydrobupropion (M4) and erythro-4'-OH-hydrobupropion (M6) were 1.8 and 2.2% of the average concentration of bupropion at steady state. Metabolite safety is typically considered to be a concern when steady state concentrations are greater than 10% of the total drug related material.²¹ Thus, it is likely unnecessary to screen these metabolites for toxicity. However, despite the low circulating concentrations of these compounds, they were abundant in urine. The overall recovery of bupropion metabolites is shown in Table 1. On average, 39% of the total oral dose was recovered in urine over the dosing interval. The amount of threohydrobupropion and its metabolites represented 26% of the dose, while only 5% and 6% of the dose was excreted as OH-bupropion and erythrohydrobupropion or their metabolites. On average, 4'-OH-bupropion, threo-4'-OH-hydrobupropion, and erythro-4'-OH-hydrobupropion

and their conjugates accounted for 0.4%, 14%, and 11% of the total oral bupropion dose excreted in urine, respectively (Table 1). Based on the amounts of threo- and erythrohydrobupropion excreted unchanged, as conjugates and as 4'-hydroxylation products, 4'-hydroxylation accounts for about 70% and 20% of the elimination of erythro- and threo- hydrobupropion, respectively, and changes in the formation of the 4'-OH-metabolites could have a substantial impact on the circulating levels of erythrohydrobupropion. To identify the enzymes responsible for the 4'-hydroxylation of bupropion, threo- hydrobupropion, and erythrohydrobupropion, each of the three compounds were incubated with a panel of recombinant CYP enzymes (see Supporting Information for experimental details). Of the recombinant CYP enzymes only CYP2C19 formed 4'-OH-bupropion from bupropion, and threo-4'-OH-hydrobupropion and erythro-4'-OH-hydrobupropion from threo and erythrohydrobupropion, respectively (data not shown).

In conclusion, we report the identification and characterization of three new metabolites of bupropion: 4'-OH-bupropion, erythro-4'-OH-hydrobupropion, and threo-4'-OH-hydrobupropion. Our findings are in agreement with previous tentative proposals of metabolite structures based on MS data but provide exact identification of the hydroxylation sites and methods for synthesizing these metabolites. The presence of hydroxylated metabolites of erythro- and threo- hydrobupropion and conjugates of an aromatic hydroxylation product(s) were previously proposed based on MS data of human urine samples.¹⁸ Similarly multiple monohydroxylation products of bupropion were proposed based on incubation data of bupropion in human liver S9 fractions and HLM.^{19,20} This data shows that 4'-hydroxylation is the predominant hydroxylation pathway for threo- hydrobupropion. This is in contrast to previous reports suggesting hydroxylation of the methyl group in addition to the aromatic hydroxylation products.^{19,20} Quantitative analysis revealed low circulating concentrations for all three new metabolites, suggesting the risk for toxicity resulting from these metabolites is likely low. However, threo-4'-OH-hydrobupropion (M4) and erythro-4'-OH-hydrobupropion (M6) were important elimination pathways for the two active metabolites of bupropion, erythro- and threo- hydrobupropion. As these metabolites were exclusively formed by CYP2C19, genetic variability in CYP2C19 activity may have large impact on bupropion activity and toxicity.

■ ASSOCIATED CONTENT

■ Supporting Information

The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acsmedchemlett.6b00189.

Full descriptions of all experimental procedures, analytical assays, compound synthesis and characterization, and supporting results and NMR spectra (PDF)

■ AUTHOR INFORMATION

Corresponding Author

*E-mail: ni2@uw.edu. Phone: 206-543-3204.

Author Contributions

The manuscript was written through contributions of all authors. All authors participated in research design. J.E.S., J.R.C., and N.I. performed experiments; J.E.S., J.R.C., N.I., and W.L.N. performed data analysis and wrote or contributed to the writing of the manuscript.

Funding

This work was funded by the National Institutes of Health grants P01 DA032507 and T32 GM007750 (to J.E.S.).

Notes

The authors declare no competing financial interest.

■ ACKNOWLEDGMENTS

The authors would like to thank Dr. Libin Xu for generously providing access to the speed vac in his laboratory. Additionally, the authors thank Dr. Venkata Narayana Vidala for his assistance collecting NMR spectra.

■ ABBREVIATIONS

HLM, Human liver microsomes; MRM, multiple reaction monitoring

■ REFERENCES

- (1) U.S. Food and Drug Administration Center for Drug Evaluation. *Wellbutrin and Welbutrin SR NDA 018644/S-041 and 02358/S-048 Approval Letter*, 2013. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/020358Orig1s053.pdf, accessed December 21, 2015.
- (2) U.S. Food and Drug Administration Center for Drug Evaluation. *Zyban NDA 20-711 Approval Letter*, 1997. http://www.accessdata.fda.gov/drugsatfda_docs/nda/97/20711_ZYBAN,%20100MG%20AND%20150MG_PHARMR_P1.PDF, accessed February 6, 2016.
- (3) U.S. Food and Drug Administration, Center for Drug Evaluation and Research. *Contrave NDA 20006Orig1s000 Approval Letter*, 2014, accessed February 6, 2016. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/200063Orig1s000Approv.pdf.
- (4) U.S. Food and Drug Administration Center for Drug Evaluation and Research (CDER). *Guidance for Industry: Drug interaction studies-study design, data analysis, implications for dosing, and labeling*, 2012, accessed May 3, 2016. <http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm292362.pdf>.
- (5) Fava, M.; Rush, A. J.; Thase, M. E.; Clayton, A.; Stahl, S. M.; Pradko, J. F.; Johnston, J. A. 15 Years of Clinical Experience With Bupropion HCl: From Bupropion to Bupropion SR to Bupropion XL. *Prim. Care Companion J. Clin. Psychiatry* **2005**, *7* (3), 106–113.
- (6) Woodcock, J.; Khan, M.; Yu, L. X. Withdrawal of Generic Budeprion for Nonbioequivalence. *N. Engl. J. Med.* **2012**, *367* (26), 2463–2465.
- (7) Rissmiller, D. J.; Campo, T. Extended-release bupropion-induced grand mal seizures. *J. Am. Osteopath. Assoc.* **2007**, *107* (10), 441–442.
- (8) Hill, S.; Sikand, H.; Lee, J. A Case Report of Seizure Induced by Bupropion Nasal Insufflation. *Prim. Care Companion J. Clin. Psychiatry* **2007**, *9* (1), 67.
- (9) Schroeder, D. H. Metabolism and kinetics of bupropion. *J. Clin. Psychiatry* **1983**, *44*, 79–81.
- (10) Findlay, J. W.; Van Wyck Fleet, J.; Smith, P. G.; Butz, R. F.; Hinton, M. L.; Blum, M. R.; Schroeder, D. H. Pharmacokinetics of bupropion, a novel antidepressant agent, following oral administration to healthy subjects. *Eur. J. Clin. Pharmacol.* **1981**, *21* (2), 127–135.
- (11) Welch, R. M.; Lai, A. A.; Schroeder, D. H. Pharmacological significance of the species differences in bupropion metabolism. *Xenobiotica* **1987**, *17* (3), 287–298.
- (12) Bondarev, M. L.; Bondareva, T. S.; Young, R.; Glennon, R. A. Behavioral and biochemical investigations of bupropion metabolites. *Eur. J. Pharmacol.* **2003**, *474* (1), 85–93.
- (13) Stahl, S. M.; Pradko, J. F.; Haight, B. R.; Modell, J. G.; Rockett, C. B.; Learned-Coughlin, S. A Review of the Neuropharmacology of Bupropion, a Dual Norepinephrine and Dopamine Reuptake Inhibitor. *Prim. Care Companion J. Clin. Psychiatry* **2004**, *6* (4), 159–166.
- (14) Damaj, M. I.; Carroll, F. I.; Eaton, J. B.; Navarro, H. A.; Blough, B. E.; Mirza, S.; Lukas, R. J.; Martin, B. R. Enantioselective Effects of Hydroxy Metabolites of Bupropion on Behavior and on Function of

Monoamine Transporters and Nicotinic Receptors. *Mol. Pharmacol.* **2004**, *66* (3), 675–682.

(15) Zhu, A. Z. X.; Cox, L. S.; Nollen, N.; Faseru, B.; Okuyemi, K. S.; Ahluwalia, J. S.; Benowitz, N. L.; Tyndale, R. F. CYP2B6 and bupropion's smoking cessation pharmacology: the role of hydroxybupropion. *Clin. Pharmacol. Ther.* **2012**, *92* (6), 771–777.

(16) Silverstone, P. H.; Williams, R.; McMahon, L.; Fleming, R.; Fogarty, S. Convulsive liability of bupropion hydrochloride metabolites in Swiss albino mice. *Ann. Gen. Psychiatry* **2008**, *7* (1), 19.

(17) Gufford, B. T.; Lu, J. B. L.; Metzger, I. F.; Jones, D. R.; Desta, Z. Stereoselective Glucuronidation of Bupropion Metabolites In Vitro and In Vivo. *Drug Metab. Dispos.* **2016**, *44* (4), 544–553.

(18) Petsalo, A.; Turpeinen, M.; Tolonen, A. Identification of bupropion urinary metabolites by liquid chromatography/mass spectrometry. *Rapid Commun. Mass Spectrom.* **2007**, *21* (16), 2547–2554.

(19) Taylor, L. C. E. The identification of in vitro metabolites of bupropion using ion trap mass spectrometry. *Rapid Commun. Mass Spectrom.* **1995**, *9*, 902–910.

(20) Chen, Y.; Liu, H.; Liu, L.; Nguyen, K.; Jones, E. B.; Fretland, A. J. The in vitro metabolism of bupropion revisited: concentration dependent involvement of cytochrome P450 2C19. *Xenobiotica* **2010**, *40* (8), 536–546.

(21) U.S. Food and Drug Administration Center for Drug Evaluation. *Guidance for Industry Safety Testing of Drug Metabolites*, 2008. www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm079266.pdf, accessed May 3, 2016.